Abstract

Final Guidance for Pharmacy Compounding of Human Drug Products Under Section 503A

Author(s): Blankenship Cynthia E

Issue: Sep/Oct 2014 - Volume 18, Number 5

View All Articles in Issue

Page(s): 379-380

Download in electronic PDF format for $75

Abstract

Related Keywords

Related Categories

Printer-Friendly Version

Related Articles from IJPC

Issue/Page View/Buy	Title/Author (Click for Abstract / Details / Purchase)
Sep/Oct 2014 Pg. 379-380	Final Guidance for Pharmacy Compounding of Human Drug Products Under Section 503A Author(s): Blankenship Cynthia E
Sep/Oct 2021 Pg. 358-362	Determining Whether a Substance is Legal to Compound with Under Section 503A of the FDCA Author(s): Cabaleiro Joe
Jul/Aug 2016 Pg. 351 View Sample	Discrepancies in the Law and the U.S. Food and Drug Administration Pharmacy Compounding Compliance Policy Guidelines Author(s): Allen Loyd V Jr
Nov/Dec 2016 Pg. 457-458	U.S. Food and Drug Administration List of Drugs NOT to be Used in Compounded Medications for Humans (The Negative List) Author(s):
Mar/Apr 2017 Pg. 95-102	U.S. Food and Drug Administration Inspections: Guide to a Successful Outcome for 503A Sterile Compounding Pharmacies Author(s): Yoch Doug
Jul/Aug 2015 Pg. 303-305	U.S. Food and Drug Administration Proposed Guidance Document: Compounding Animal Drugs from Bulk Substances Author(s): Miller David G
May/Jun 2014 Pg. 208	The U.S. Food and Drug Administration Responds to the International Academy of Compounding Pharmacists' Outsourcing Letter Author(s): Miller David G
Nov/Dec 2015 Pg. 487-488	U.S. Food and Drug Administration "Evaluation Criteria" for Difficult to Compound Drugs Author(s): Allen Loyd V Jr
Sep/Oct 2017 Pg. 356	PreScription: 2017 Pharmacy Compounding Issues: The U.S. Food and Drug Administration, Harzardous Drugs, and Wasted Drugs Author(s): Allen Loyd V Jr
Mar/Apr 2022 Pg. 100-109	Allowing Compounding Pharmacies to Address Drug Shortages Author(s): Broughel James
Jul/Aug 2020 Pg. 296-297	Finally: A Final U.S. Food and Drug Administration Memorandum of Understanding, but It's Flawed Author(s): Brunner Scott
Mar/Apr 2015 Pg. 104-106	Standing Together Fixing the Drug Quality and Security Act Author(s): Miller David G
Nov/Dec 2016 Pg. 477-479	The "Lists": What Do They Mean? Author(s): Voliva John
Sep/Oct 2015 Pg. 389-390	Nominations of Difficult to Compound Drugs to the U.S. Food and Drug Administration--Pharmacy Compounding Advisory Committee: Part 1 Author(s): Allen Loyd V Jr
Nov/Dec 2015 Pg. 449-450	International Academy of Compounding Pharmacists' Legislative Regulatory Update: Take Action! Stop the U.S. Good and Drug Administration's Misguided Veterminary Guidance Author(s): Miller David G
Jan/Feb 2014 Pg. 35-36	U.S. Food and Drug Administration Requests for Input on HR 3204 Enactment: The Drug Quality and Security Act of 2013 Author(s): Miller David G
Jan/Feb 2005 Pg. 44-46	The US FDA List of Drugs Not to Be Used in Compounded Medications for Humans (the "Negative List") Author(s): Allen Loyd V Jr, Ashworth Lisa D
Jan/Feb 2023 Pg. 22-23	The U.S. Food and Drug Administration Takes Aim at Compounded Thyroid Hormone Author(s): Brunner Scott
Nov/Dec 2023 Pg. 474-481	Nonsterile Basics of Compounding: Using U.S. Food and Drug Administration-approved Commercial Products as Ingredients Author(s): Allen Loyd V Jr
Mar/Apr 2022 Pg. 92	PreScription: Comments on the FDA Guidance "Compounded Drug Products That Are Essentially Copies of a Commercially Available Drug Product Under Section 503A of the Federal Food, Drug, and Cosmetic Act: Guidance for Industry" Author(s): Allen Loyd V Jr